U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07060560) titled 'Presepsin Diagnostic Performance in Severe Burn Sepsis' on July 02.
Brief Summary: This study enrolls approximately 270 adult patients with severe burns covering at least 20% of total body surface area to evaluate how well the blood biomarker presepsin diagnoses sepsis early in this high-risk population. Sepsis-a life-threatening condition caused by an exaggerated immune response to infection-is particularly urgent to detect promptly in burn patients. Participants will undergo blood tests for presepsin at predefined time points, and these results will be compared to C-reactive protein (CRP), procalcitonin (PCT) levels, Sepsis-3 clin...